kieferpix-istockphoto-com-usa-

Kieferpix / iStockphoto.com

5 February 2019Americas

Fed Circuit refusal paves way for Suboxone generics

Rivals of British pharmaceutical company Indivior will soon be able to sell generic versions of opioid addiction treatment Suboxone film (buprenorphine and naloxone) following a ruling of the US Court of Appeals for the Federal Circuit.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Indivior loses battle over Suboxone generic

22 November 2018 The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.

Indivior to launch generic after SCOTUS refuses petition

22 February 2019 Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

12 July 2019 Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

More on this story

Indivior loses battle over Suboxone generic

22 November 2018 The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.

Indivior to launch generic after SCOTUS refuses petition

22 February 2019 Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

12 July 2019 Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

More on this story

Indivior loses battle over Suboxone generic

22 November 2018 The US Court of Appeals for the Federal Circuit vacated a preliminary injunction against India-based Dr Reddy’s earlier this week, in a blow for addiction treatment drug producer Indivior.

Indivior to launch generic after SCOTUS refuses petition

22 February 2019 Indivior has launched a generic version of its opioid addiction drug Suboxone (buprenorphine and naloxone) Film, one day after the US Supreme Court denied its request to put a lower court’s ruling on hold.

Reckitt Benckiser to pay $1.4bn over opioid treatment sales

12 July 2019 Reckitt Benckiser has agreed to pay a $1.4 billion fine to settle a US investigation into the sales and marketing of opioid addiction treatment Suboxone film by its former prescriptions business.

More features

Bayer gains exclusive licence for heart drug in Japan

EPO delivers key Novo Nordisk, GSK and Inhibrx rulings

McGuireWoods expands team with ex-Novo Nordisk GC

Paul, Weiss swoops for senior duo from Weil, Gotshal

UPC bans Meril Life Sciences from selling infringing heart valve

SCOTUS denies Alvogen unit's appeal to sell Bausch Xifaxan generic

Kathi Vidal to rejoin previous firm as partner following USPTO departure

GSK triumphs in EPO appeal, revoking Pfizer patent